Theravance Biopharma to present ampreloxetine clinical development program at AAS symposium.

Theravance Biopharma will present four presentations at the 36th International Symposium on the Autonomic Nervous System, including topline results from the Phase 3 CYPRESS study of ampreloxetine, a potential treatment for symptomatic neurogenic orthostatic hypotension in multiple system atrophy. The study's results are expected in Q1 2026.